Back to Studies

Study analysis · Nature Communications · 2025

What if you could lose twice as much fat—without losing a single pound of muscle?

Blocking two proteins in the body lets weight-loss drugs like Ozempic burn double the fat while keeping your muscles intact.

Reading level
Very low certainty
Level 1b · Individual RCTAssociation, not causationNo causal claims

Overview

What the study found

The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.

In simple terms

This study looked at how a special treatment affected the bodies of male mice and monkeys, and found that they lost more fat and kept more muscle when given the treatment. But it didn't randomly assign animals to groups or hide which animals got the treatment, so we can't be sure the treatment caused the changes — maybe something else did.

What’s the bottom line?

Weight-loss drugs like semaglutide make you lose muscle along with fat. This study tried a new combo treatment that blocks two natural signals that tell your body to shrink muscles.

How strong is this study?

The scientists did a good job measuring things like muscle and fat, but they didn't play fair when giving out the treatments — they didn't flip a coin to decide who got what, and they knew who got the real medicine. That makes it harder to trust the results, because maybe the animals that got the treatment were already different to begin with.

Reporting

0 / 100

  • COI disclosureconflicts of interest not disclosed
  • Data availabilitydata not shared
  • Code availabilitycode not shared
Methodology

35 / 100

  • Randomizationrandomization unclear
  • Blindingblinding unclear
  • Control group+15/15
  • Sample size (n=30)+2.8/20
  • Follow-up+10/10
Publication

100 / 100

Statistical

54 / 100

  • P-values+15/15
  • Effect size+20/20
  • Confidence intervalsno confidence intervals
  • Pre-registrationnot pre-registered

Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.

Where it sits

RCT reviews

Max 100

Randomized Trials

Max 90

Reviews of Cohort Studies

Max 85

Cohort Studies

Max 72

Reviews of Case-Control Studies

Max 63

Case-Control Studies

Max 58

Cross-Sectional & Case Series

Max 50

Expert Opinion

Max 5
StrongerWeaker
Randomized Trials
Level 1b
14

14 / 100

Probability of being correct

Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.

This design cannot establish causation — the findings describe an association, not a cause. Although the study uses multiple groups and compares interventions, randomization and blinding are explicitly stated as unknown or not used, which prevents classification as an RCT. Without confirmed randomization and blinding, the study cannot establish causation and is downgraded to a case series due to high risk of bias and lack of methodological rigor required for causal inference.

Critical COI

Critical conflicts — study credibility is severely compromised

The study tests fully human antibodies (trevogrumab and garetosmab) developed by the authors' institution, which are directly tied to the therapeutic intervention being evaluated, and the results strongly favor the efficacy of these proprietary compounds, suggesting the study serves as a de facto marketing vehicle for industry-developed biologics.

Industry Funded
Funder Involved

Conflict Details

multiple authors
Patent
Employee

Not specified (likely biotech entity behind trevogrumab/garetosmab): Authors developed and hold intellectual property rights to the GDF8 and activin A blocking antibodies (trevogrumab and garetosmab) being tested in the study.

No funding statement, no COI disclosure section, and no mention of independent oversight. The study is entirely focused on validating proprietary antibodies developed by the authors, with no third-party funding or independent validation. The results are presented with strong positive outcomes that directly support commercial development of the authors' own biologics, raising severe bias concerns.

Key takeaways

  1. 01

    In mice, the combo lost twice as much fat as semaglutide alone.

  2. 02

    In monkeys, it built more muscle and lost more fat over 20 weeks, while also improving blood sugar and cholesterol.

  3. 03

    Yes—preserving muscle while losing more fat could make weight loss healthier and more sustainable, reducing rebound weight gain and metabolic risks.

Surprising findings

  • Dual blockade of GDF8 and activin A alone (without semaglutide) improved body composition in mice and primates—even without appetite suppression.Most people assume muscle growth or fat loss requires calorie restriction or drugs like semaglutide. But blocking just these two proteins improved fat loss and muscle gain on its own—suggesting they’re master regulators of body composition.
  • Fat loss doubled in mice with the combo treatment despite identical total weight loss to semaglutide-only group.It’s counterintuitive that two groups could lose the same weight but one loses twice as much fat—proving that ‘weight loss’ is a misleading metric when muscle is involved.

Practical takeaways

If you're on or considering GLP-1 drugs like semaglutide, prioritize resistance training and high-protein intake to minimize muscle loss—until targeted therapies like GDF8/activin A blockers become available.

This study was done in mice and monkeys; no human trials have confirmed these effects yet. The blocking antibodies are still experimental.

medium confidence

Why this study matters

Double the Fat Loss, Same Weight Loss

In obese mice, combining semaglutide with dual blockade of GDF8 and activin A led to approximately twice the fat loss compared to semaglutide alone—despite identical total weight loss. This means muscle preservation directly enhanced fat mobilization, not just overall weight reduction.

Most people think weight loss is just about the scale, but this shows body composition matters more: you can lose the same weight but burn way more fat if you protect muscle—making results healthier and more sustainable.

Muscle Growth on a Diet? Yes, in Primates

In obese non-human primates treated for 20 weeks, the combo of semaglutide + GDF8/activin A blockade didn’t just preserve muscle—it actually increased lean mass while also boosting fat loss, improving HbA1c, LDL, and HDL cholesterol more than semaglutide alone.

This flips the script: usually, dieting makes you weaker. Here, a drug combo made monkeys stronger and healthier at the same time—hinting at a future where weight loss = muscle gain.

Why Muscle Loss Isn’t Just ‘Bad Luck’

The study reveals muscle loss during GLP-1 therapy isn’t inevitable—it’s driven by evolutionary mechanisms that shut down muscle to save energy during food scarcity. Blocking GDF8 and activin A overrides this ancient survival signal.

It’s not your fault you lose muscle on weight-loss drugs—it’s your body’s ancient survival mode. Now science may have found a way to hack it.

Want the whole report?

Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.

Standing

Who’s using this study?

The videos and claims on this site that lean on this study, and the researchers who wrote it.

2 videos from 2 different creators cite this study, drawing 6 claims from it.

Physionic
The Ultimate Peptide Stack? Gain Muscle, Lose Fat!
Linked in description
Supports
Jeremy Ethier
Targeting Belly Fat Is POSSIBLE?! (60-Day MRI Experiment)
Citing claim
1 video linked in descriptions, 1 referenced through claims.